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Abstract 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of obscure etiology. Multiple genetic studies have 
been conducted to advance our understanding of the disease, employing a variety of techniques such as linkage 
mapping in families, to genome-wide association studies and sequencing based approaches such as whole exome 
sequencing and whole genome sequencing and a few epigenetic analyses. While major progress has been made, the 
majority of the genetic variation involved in ALS is yet to be undefined. The optimal study designs to investigate ALS 
depend on the genetic model for the disease, and it is likely that different approaches will be required to map genes 
involved in familial and sporadic disease. The potential approaches and their strengths and weaknesses are discussed. 
Keywords 
amyotrophic lateral sclerosis, genetic study, epigenetic study, genome-wide association study, next-generation 
sequencing study 
 
 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a progressive 
neurodegenerative disease caused by selective loss of upper 
and lower motor neurons (common clinical manifestations 
of ALS are shown in Fig. 1). The disease typically has a 
late onset and is often fatal within 3 to 5 years. No effective 
treatments exist for ALS; the only current treatment is 
riluzole, which is thought to affect glutamate metabolism 
and only modestly extends survival time (Miller and others 
2012). The worldwide incidence of ALS is approximately 
0.3 to 7.0 new cases per 100,000 each year (Cronin and 
others 2007). Nearly 10% of ALS cases are classified as 
familial ALS (fALS) (Byrne and others 2011), wherein a 
family history of the disease is known. In these families, 
the pattern is primarily consistent with autosomal dominant 
inheritance, although other hereditary patterns have been 
found (Siddique and Ajroud-Driss 2011). Approximately 
half of familial cases can be explained by specific genes, 
the majority of which appear to be rare highly penetrant de 
novo mutations in each family involved. The 90% of ALS 
cases where no family history is present are termed 
sporadic ALS (sALS). The genetic etiology of both sALS 
and nearly ~30% of fALS (European descent) remains 
obscure. Whether sALS is primarily polygenic, because of 
highly penetrant de novo mutations or inherited mutations 
with low penetrance is unclear, and this knowledge will be 
critical in the design of future gene-mapping studies. 
Detailed information regarding ALS-related genes is 
available via the amyotrophic lateral sclerosis online 
genetics database (http://alsod.iop.kcl.ac.uk/), the ALS 
mutation database (https://reseq.lifesciencedb.jp/ 
resequence/SearchDisease.do?targetId=1), and the 
ALSGene database (http://www.alsgene.org). 
Exploring the genetic etiology of ALS has provided 
fundamental insights into the process underlying neuron 
degeneration and majority of our current knowledge of 
ALS. On this basis, considerable efforts have been 
devoted to unravel pathophysiological mechanisms.  
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Figure 1. Common clinical methods and manifestations in amyotrophic lateral sclerosis (ALS). (A) LMN = lower motor 
neurons; UMN = upper motor neurons. (B) EMG = electromyography: Nerve conduction study and needle electromyography 
remain the most important diagnostic testing for ALS. The former is used primarily to help rule out other disorders and the 
latter to establish evidence for widespread active denervation and chronic reinnervation. Evidence for denervation in ALS on 
needle EMG includes (B-1)—fibrillation potentials and positive sharp waves and (B-2)—pathologic interference pattern. (C) This 
MRI demonstrates increased T2 signal within the posterior part of the internal capsule and can be tracked to the subcortical 
white matter of the motor cortex, outlining the corticospinal tract. (D) Routine muscle biopsy: ALS (D-1—hematoxylin and 
eosin frozen section 200× and D-2—NADH stain 200×) may show grouped atrophy; D-2—Small muscle fibers stain darkly on 
NADH. 
 
Multiple pathogenic processes have been reported that 
support the view of multiple routes to a common 
endpoint of progressive upper motor neuron and lower 
motor neuron loss (Fig. 2). 
Since the discovery of mutations in the SOD1 gene 
causing fALS in 1993(Rosen and others 1993), a 
growing number of causative genes and related loci have 
been identified (Table 1), including TARDBP, FUS and 
C9orf72. A breakthrough in the understanding of ALS 
pathogenesis was the discovery that TDP-43 is a central 
component of the ubiquitin-positive neuronal inclusions 
that are the pathological hallmark in ALS (Neumann and 
others 2006). TDP-43 is an RNA-binding protein that is 
encoded by the gene TARDBP and mutations were 
subsequently found in rare ALS case. The discovery of 
ALS causing mutations in several other genes whose 
encoded proteins are involved in RNA processing has 
further implicated this molecular pathway in the 
pathogenesis in ALS. These include mutations in FUS, 
encoding an RNA-binding protein with similarity to 
TDP-43 (Kwiatkowski and others 2009; Vance and 
others 2009) and a repeat expansion in C9orf72, 
associated with RNA foci in cells from ALS cases 
(DeJesus-Hernandez and others 2011). A growing 
number of genes have been implicated in ALS by 
discovery of rare sequence variants in ALS cases, 
including VCP (Wu and others 2012) and PFN1 
(Johnson and others 2010), although molecular evidence 
supporting a role as an ALS causative gene is not 
entirely convincing for all genes and requires further 
validation. 
In order to advance our understanding of the 
aetiopathogenesis of ALS, extensive candidate gene and 
hypothesis-free gene-mapping studies have been 
pursued. In recent years, revolutions in genetic 
techniques have taken place. The development of 
genome-wide association studies (GWAS) has provided 
a powerful tool for the identification of common 
variants associated with disease, and next-generation 
sequencing (NGS) methods have proven similarly 
effective in mapping mutations underlying single gene 
diseases. Multiple GWAS and NGS studies have 
collectively identified a number of novel genetic 
variants associated with increased risk of ALS 
development. These approaches, that make assumptions  
 
 
 
 
 
 
Figure 2. Proposed molecular targets and mechanisms underlying neurodegeneration in amyotrophic lateral sclerosis (ALS). 
Many of the initial pathological changes in models of ALS occur in the peripheral motor system, supporting a “dying-back” view of 
pathogenesis, though a causal primacy of lower motor neuron over upper motor neuron degeneration remains an issue of 
debate. The transgenic SOD1 mouse model has been used extensively to dissect the likely pathogenic mechanisms. Many of these 
illustrated pathways are mechanisms of cell death common to a range of neurological disorders whereas more recent genetic 
discoveries have yet to be elucidated at a molecular level. Pathophysiological mechanisms involved in ALS might include 
combinations of glutamate excitoxicity, generation of free radicals, mutant enzymes, as well as disruption of axonal transport 
processes and mitochondrial dysfunction. Mutations in several ALS causative genes are related to the formation of intracellular 
aggregates. Mitochondrial dysfunction, which is associated with increased production of reactive oxygen species and aggregates of 
SOD1, might induce increased susceptibility to glutamate-mediated excitotoxicity, disturbance in energy production and 
apoptosis. Activation of microglia results in secretion of cytokines resulting in further toxicity. 
 
 
 
 
 
 
 
 
 
 
Table 1. Causative Genes in Amyotrophic Lateral Sclerosis (ALS). 
Gene Location Inheritance Allelic Disorders (OMIM#) 
Encoded Protein 
function Ref. Replications 
SOD1* 21q22.1 AD or AR — Superoxide dismutase Rosen and others 
(1993) 
1 
C9ORF72* 9p21.2 AD ALS and/or FTD  Unknown DeJesus-Hernandez 
and others (2011), 
Renton and others 
(2011) 
1 
FUS* 16p11.2 AD or AR; de 
novo 
ALS with or without FTD, 
ETM4 (614782), 
translocation fusion genes 
associated with tumors 
RRM protein, RNA 
metabolism 
Kwiatkowski and 
others (2009), 
Vance and others 
(2009) 
1 
OPTN** 10p15-14 AD or AR POAG (137760) Vesicular trafficking, 
signal transduction 
Maruyama and others 
(2010) 
1 
SETX* 9q34 AD (juvenile 
onset) 
SCAR1 (606002) DNA/RNA helicase; 
transcription 
termination 
Chen and others 
(2004) 
1 
UBQLN2* Xp11.21 XD ALS with or without FTD Ubiquilin protein family, 
protein degradation 
and autophagy 
Deng and others 
(2011) 
1 
ALSIN* 2q33 AR (juvenile 
onset) 
PLSJ (606353), IAHSP 
(607225) 
Guanine nucleotide 
exchange factor; 
AMPA receptor 
trafficking, 
endosome/membrane 
trafficking  
Hadano and others 
(2001), Yang and 
others (2001) 
1 
VAPB* 20q13.33 AD  SMAFK (182980) ER organization Nishimura and others 
(2004) 
1 
SPG11* 15q14 
15q15.1- 
AR (juvenile 
onset) 
SPG Spatacsin, intracellular 
trafficking, motor 
neuron and axon 
development 
Orlacchio and others 
(2010) 
1 
TARDBP** 1p36 AD ALS with or without FTD, 
FTLD 
RRM protein, RNA 
metabolism 
Sreedharan and 
others (2008) 
2 
DCTN1** 2p13 AD HMN7B (607641), Perry 
syndrome (168605) 
Dynactin; axonal 
transport of vesicles 
and organelles 
Munch and others 
(2004) 
2 
SQSTM1** 5q35.3 AD PDB Autophagy, ubiquitin 
proteasome pathway 
Fecto and others 
(2011) 
2 (No 
segregation 
was shown) 
FIG4** 6q21 AD or AR CMT4J (611228) Phosphatidinositol 3,5-
biphosphate 5-
phosphatase; 
membrane trafficking, 
endolysosome 
function 
Chow and others 
(2009) 
2 
ANG** 14q11 AD — Ribonuclease A 
superfamily; RNA 
functions 
Greenway and others 
(2006) 
2 
DAO** 12q24 AD — Oxidative deamination 
of D-amino acids 
Mitchell and others 
(2010) 
2 
VCP*** 9p13.3 AD ALS with or without FTD, 
MSP (167320) 
AAA+ family; 
endocytosis and 
vesicular trafficking 
Johnson and others 
(2010) 
3 
PFN1*** 17p13.2 AD — Inhibits actin 
polymerization 
Wu and others (2012) 3 
CHMP2b** 3p11.2 AD FTD3 Chromatin 
modifying/CHMP 
family, endocytosis 
and vesicular 
trafficking, protein 
degradation 
Parkinson and others 
(2006) 
4 
PRPH** 12q12 AD — Type III intermediate 
filament protein; 
Gros-Louis and 
others (2004), 
5 
	  
	  
	  
Axonal regrowth Leung and others 
(2004) 
TAF15** 17q12 AD  Translocation fusion genes in 
EMC 
RRM protein, RNA 
metabolism 
Ticozzi and others 
(2011) 
5 
EWSR1** 22q12.2 AD Translocation fusion genes in 
ESFT, PNE (612219), EMC 
RRM protein, RNA 
metabolism 
Couthouis and others 
(2012) 
5 
HNRNPA1*** 12q13.1 AD MSP RRM protein, RNA 
metabolism 
Kim and others 
(2013) 
6 
SIGMAR1* 9p13.3 AD (juvenile 
onset) 
— ER chaperone Al-Saif and others 
(2011) 
6 
ATXN2 12q24  SCA2 (183090) Polyglutamine protein, 
RNA metabolism 
Elden and others 
(2010) 
7 
NEFH** 22q12.2 AD — Neurofilament, heavy 
polypeptide 
Renton and others 
(2011) 
7 
SMN1 5q13.2  SMA (253300) RRM protein, RNA 
metabolism 
Corcia and others 
(2002), Blauw and 
others (2012) 
7 
Mode types: AD = autosomal dominant; AR = autosomal recessive; XD = X-linked dominant. *, **, and *** indicate the gene was first identified 
in ALS patients by positional cloning, candidate gene screening, and whole exome sequencing (WES), respectively. SCA2 = spinocerebellar ataxia-
2; CMT4J = Charcot–Marie–Tooth, autosomal recessive, type 4J; PLSJ = primary lateral sclerosis, juvenile; IAHSP = infantile onset ascending 
spastic paralysis; SCAR1 = spinocerebellar ataxia, autosomal recessive; ETM4 = hereditary essential tremor-4; SMAFK = spinal muscular atrophy, 
late-onset, Finkel type; POAG = primary open angle glaucoma; MSP = multisystem proteinopathy; FTD3 = frontotemporal dementia, 
chromosome 3-linked; EMC = extraskeletal myxoid chondrosarcoma; ESFT; Ewing sarcoma family of tumors; PNE = peripheral 
neuroepithelioma; PDB = Pagets disease of bone; SPG = spastic paraplegia. Replication: 1. Linkage in at least one family (logarithm of odds [LOD] 
>3). The mutations/s segregates with disease, is not found in normal samples, and mutations were subsequently found in sALS or other small 
families; 2. Variants were found to segregate in multiple small families (but were too small to achieve genome-wide significance in linkage analysis) 
as well as found in multiple sporadic cases and are not found in normal samples; 3. Gene contains variants that segregate in multiple small families 
but have not been reported in sporadic cases, and are not found in normal samples; 4. Variants described in one small family and multiple 
sporadic cases and are not found in normal samples. Functional tests assessing the affect of the mutation on the protein function support a role in 
ALS; 5. Mutations have been reported in multiple sporadic cases and not in normal samples. Functional tests assessing the affect of the mutation 
on the protein function support a role in ALS; 6. Rare variants have been found in the gene in only one family; 7. copy number variants 
(CNV)/particular alleles present in ALS patients significantly more than control. 
 
about the underlying genetic architecture of disease 
especially for sporadic cases, can be complex to perform 
(Hardiman and others 2007), and depend on accurate 
clinical phenotyping for success. Thus, whilst many 
robust associations have been made with rare mutations 
and common variants in ALS, false positive findings 
have also occurred (Garber 2008). Given this context it 
is important to examine the performance and limitations 
of GWAS along with the expectations for NGS in the 
study of ALS. 
Are Sporadic and Familial ALS 
Different? 
The genetic architecture of common diseases can be 
investigated by studying the recurrence rate in relatives 
of affected individuals (Risch 1987). A twin study has 
shown that for ALS the concordance rate in identical 
monozygotic twins is ~10%, whereas the concordance 
rate in dizygotic twins is very low (0/122 twins) as is the 
parent-offspring concordance rate (~1%) (Al-Chalabi 
and others 2010). From the twin concordance values, the 
heritability of ALS has been calculated to be 61%, 
taking into account the low population prevalence of the 
disease (Al-Chalabi and others 2010). For monogenic 
autosomal diseases, the parent–offspring rate is 
generally high unless the penetrance is low (Risch 
1990a, 1990b). Thus the low parent–offspring and twin 
concordance rates are most consistent with models 
involving either multiple variants, either common or 
rare, especially variants with low penetrance, 
contributing to each case, rather than single highly 
penetrant variants in each individual. 
The boundary between sporadic and familial ALS is 
becoming far more blurred than their nomenclature 
suggests. Although it has been reported that 10% of 
ALS is familial, when the genealogy of sALS cases is 
investigated more thoroughly, the prevalence of a family 
history increases to 20% in some prospective studies 
(Chio and others 2011; van Es and others 2010). 
Establishing familiality is difficult in late onset diseases, 
and it is likely that this leads to underestimation of the 
familiality of ALS. It is often quite difficult for adult 
children of ALS patients to accurately recall their 
parent’s symptoms, particularly if decades have passed 
since the event, which occurred when the diagnosis of 
ALS may not have been considered. 
The idea that sALS and fALS may share a diverse 
genetic aetiology is consistent with the observation that 
sALS and fALS are clinically indistinguishable 
(Andersen and others 1997), and because of increasing 
demonstration that “sporadic” cases are often caused by 
the same mutations that have previously been reported 
in familial cases. Familial and sporadic cases share 
histopathological characteristics; for example, 
superoxide dismutase 1 (SOD1)–positive and TAR 
DNA-binding protein 43 (TDP-43)–positive inclusions 
have been found in both sALS and fALS (Bosco and 
others 2010; Forsberg and others 2010). Moreover, first-
 
 
 
degree relatives of patients with ALS have an increased 
incidence compared with unrelated individuals (Fallis 
and others 2009). Additionally, the hexanucleotide 
repeat expansion mutation in the C9orf72 gene is 
associated with a founder haplotype. The expansion is 
found both in familial cases and in a high proportion of 
“sporadic” ALS cases (21% of Finnish sALS) (Renton 
and others 2011), and, albeit at low frequency, in control 
populations (prevalence of expansions 0.15% in 1958 
British Birth Cohort) (Beck and others 2013). The 
C9orf72 expansion occurs on a common risk haplotype, 
which is prone to expansion of the hexanucleotide repeat 
for reasons that are not understood. Thus whilst the 
common founder haplotype is prevalent in the 
community, further mutation (expansion of the 
hexanucleotide repeat) on this haplotype may lead to 
ALS, and would at least partially explain the occurrence 
of sALS due to C9orf72 expansions in families with no 
previous history of the disease (DeJesus-Hernandez and 
others 2011). The alternative is that the repeat expansion 
is not fully penetrant and modifier loci or environmental 
factors are also required for C9orf72 repeat expansions 
associated ALS pathogenesis. 
Combined, this evidence indicates that sALS 
diagnosis does not exclude the possibility of familial 
inheritance even with “definite” negative familial 
histories. The term “sporadic” has also been used for 
other neurological disorders such as autism, in which a 
high degree of genetic heterogeneity has now been 
uncovered (O’Roak and others 2012). We agree with the 
suggestion that the term “sporadic” is inappropriate as it 
suggests only non-genetic causes, whereas the term 
“isolated” ALS might be more accurate as it 
encompasses environmental and/or genetic causes. 
Prevalent Heterogeneity in 
Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis demonstrates both clinical 
and genetic heterogeneity, but to date genetic 
explanations for the clinical heterogeneity have been 
incomplete. 
Three clinical variants are widely recognized, 
including progressive bulbar palsy (PBP), classic onset 
and progressive muscular atrophy (PMA) (del Aguila 
and others 2003). By and large, bulbar onset appears to 
advance more rapidly and PMA may have a better 
prognosis (del Aguila and others 2003; Norris and others 
1993). Besides these three, other forms have been 
recognized in recent years. Brachial amyotrophic 
diplegia (flail arm syndrome, FA) and the 
pseudopolyneuritic variant (flail leg syndrome, FL) are 
instructive examples. Compared with classic type, FA 
and FL have a prolonged course (Wijesekera and others 
2009). Furthermore, these clinical variants appear to 
have a male predominance, which may suggest that 
other gender-related genes are involved, although such 
genes are yet to be identified (Gamez and others 1999). 
Recent genetic studies have taken clinical 
heterogeneity into account, but have yet to identify 
individual variants or genomic profiles associated with 
different ALS clinical patterns (Dunckley and others 
2007; Kwee and others 2012). An Italian study (Orsetti 
and others 2011) involving 228 ALS patients reported a 
potential correlation between the upper motor neuron-
predominant phenotype and KIFAP3. However, these 
findings have not been replicated in subsequent studies 
(Table 3). This may be because in some studies the 
clinical subgroups were not clearly defined in the same 
manner as the Italian study, and in others the study 
power was likely insufficient. Whatever the explanation, 
clear genotype–phenotype correlation to explain the 
different presentations is lacking. 
Studies of ALS have been particularly successful in 
identifying disease-causative mutations (Table 1). 
Clinical heterogeneity is seen in unrelated ALS cases 
that share the same mutation, but also in carriers from 
within the same family. On the other hand families with 
mutations in different genes are often clinically 
indistinguishable. In addition to the locus heterogeneity, 
there is also extensive allelic heterogeneity. For 
example, at least 160 disease-causative mutations in 
SOD1 have been reported (Birve and others 2010; 
Zinman and others 2009). If genetic or locus 
heterogeneity is as extensive in sporadic ALS, genetic 
studies will struggle to identify the genes involved, 
unless quite large case and control cohorts are studied. 
Amyotrophic Lateral Sclerosis 
Studies in Different Ethnic 
Populations 
Genetic differences between ethnic groups are often a 
nuisance in genetic studies. Nonetheless, they can be 
useful tools where the variation in linkage 
disequilibrium and polymorphism frequencies between 
populations provides useful contrasts that can be 
informative in identifying key disease-associated 
variants. There are no apparent differences in the 
incidence or prevalence of ALS between ethnic groups. 
However, several spatial clusters of ALS have been 
reported that may be explained by a higher frequency of 
particular mutations in geographical regions. A spatial 
cluster of ALS in south-eastern Finland (Sabel and 
others 2003) is likely explained by the high occurrence 
of the C9orf72 hexanucleotide repeat in ALS cases from 
Finland. Similarly, although the C9orf72 repeat 
expansion is generally rare in Japanese ALS cases, it has 
been reported in cases from the Kii peninsula where 
another cluster had also been observed (Yoshida and 
others 1998). Perhaps of more interest for disease 
progression is the SOD1 mutation (D90A) that has been 
	  
	  
	  
shown to be responsible for slowly progressive, 
autosomal recessive ALS in Sweden and Finland 
(Andersen and others 1997). A total of 1% to 2.5% of 
the population are heterozygous carriers of this 
mutation, yet do not develop ALS. However, in other 
geographical locations, heterozygous carriers of the 
same mutation develop classical ALS (Robberecht and 
others 1996). Whether this is caused by environmental 
effects or modifier genetic effects is unknown. Thus, 
there is likely to be genetic heterogeneity between ethnic 
groups, providing new information about the genetic 
causes of a disease. To date nearly all large-scale genetic 
studies in ALS have been performed in populations of 
European descent, with only limited studies performed 
in Asians, and none that the authors are aware of in 
African Americans. Such studies would be beneficial in 
elucidating the genetic contribution to ALS globally. 
Genome-wide Association Studies in 
Amyotrophic Lateral Studies 
Traditional genetic strategies such as linkage studies or 
candidate gene sequencing have had major success in 
finding mutations in familial ALS. However, their 
potential is limited by the low availability of families 
with recurrent disease, challenges associated with family 
studies in late onset diseases, and by the low power of 
linkage analysis to identify low-penetrant variants. As 
cases are often misdiagnosed and/or have died before 
recurrence occurs within individual families, few 
families with DNA samples from multiple affected and 
unaffected members from multiple generations are 
available. The variability in the age of onset, even 
within families, means that coding unaffected members 
of families can be misleading, when they may develop 
ALS later in life. Additionally there are now several 
examples of ALS mutations with incomplete penetrance 
(for example in SOD1 (Gamez and others 2011) and 
TARDBP (Orru and others 2012)), the presence of which 
can also affect linkage studies. Given these challenges 
with traditional linkage mapping approaches, and the 
possibility that many sALS cases may be because of low 
penetrance, possibly common founder variants, in recent 
years alternate methods involving GWAS and exome 
sequencing have been employed to identify the genetic 
variants. 
The Design of Amyotrophic Lateral 
Sclerosis GWAS 
Genome-wide association studies identify loci associated 
with disease where cases or controls share stretches of 
DNA (haplotypes) in which a disease-causing mutation has 
occurred in a distant common founder. By typing SNPs 
across the genome, these disease-associated haplotypes are 
identified by differences in frequencies of SNPs between 
cases and controls because of the marker SNPs being found 
on the same haplotype as the disease-causing variant, a 
feature termed ‘linkage disequilibrium’. Association in 
GWAS studies may thus represent true association (where 
the genotyped, associated SNP is directly involved in the 
disease), linkage disequilibrium (where the genotyped, 
associated SNP is merely a marker for a haplotype bearing 
the true disease-causing variant), population stratification 
(where differences in ethnicity between cases and controls 
lead to spurious associations), technical artifacts in the 
genotyping (such as batch effects, differential missingness), 
or cryptic relatedness (where the assumption that cases and 
controls are not closely related to one another is not met, 
leading to inflation of association test statistics). Careful 
quality control checks of GWAS data have been developed, 
and if these are used then findings that achieve genome-
wide significance (generally thought to be P < 5 × 10−8, 
although this does depend on the prior probability of a true 
positive finding) have generally proven robust and 
reproducible. 
Sample size requirements for GWAS are large and 
challenging to achieve, particularly for low frequency 
diseases such as ALS (Purcell and others 2003) (Figure 
3). For most diseases, this has led to the formation of 
large consortia pooling resources to achieve adequate 
power. Where separate studies are performed, meta-
analysis methods and software for either the original 
genotype data or summary statistics have been 
developed to achieve sufficient power. There has been 
some success employing GWAS in ALS (Table 2), and 
some of that raw data has been made publicly available 
to augment resource for other studies of ALS. The 
largest GWAS to date in ALS involved 6100 cases and 
7125 controls (Fogh and others 2014). Although this is 
evidently a large study, the sample size requirement 
presented in Figure 1 suggest that even larger studies 
will be required to identify further loci, particularly to 
identify low frequency variants, even if they have quite 
high penetrance. For example, to achieve 80% power to 
identify a variant with minor allele frequency of 1% and 
odds ratio for disease of 5 will require >10,000 cases to 
be studied! Such sample sizes have been achieved for 
diseases less common than ALS. For example, in 
Crohn’s disease, which has a prevalence of 0.1%, more 
than 77,000 cases have been reported in a single study 
(Jostins and others 2012). 
 
 
 
 
 
Figure 3. Genetic power calculation for the sample size according to the different minor allele frequencies (MAFs). 
 
Table 2. Main Results Reported by Genome-wide or Large-scale Strategies in ALS Studies. 
No. Ref. SNP Chr Gene Description 
Original Study 
MAF 
Pooled OR (95% CI) 
Pooled P Value 
Controls Patients P Value 
Bonferroni 
Correction 
1 van Es and 
others 
(2007) 
rs2306677 12 ITPR2 A calcium 
channel on 
the 
endoplasmi
c reticulum 
0.07 0.11 1.58 (1.30-1.91) 3.28 × 10–6 Exceed 
2 Dunckley 
and others 
(2007) 
rs6700125 1 FLJ10986 
(FGGY) 
Unknown, 
possible 
role in 
metabolism 
0.32 0.41 1.35 (1.13-1.62) 6 × 10−4 Exceed 
3 Cronin and 
others 
(2008) 
rs10260404 7 DPP6 A 
transmemb
rane 
protein 
binding A-
type 
neuronal 
potassium 
channels 
0.34 (Irish) 0.42 (Irish) 1.37 (1.2-1.56) 2.53 × 10–6 Failed 
4 van Es and 
others 
(2009) 
rs12608932 19 UNC13A Encoding 
presynaptic 
proteins 
found in 
central and 
neuromusc
ular 
synapses 
0.37 0.40 1.2 2.50 × 10−14 Exceed 
5 rs2814707 9 MOBKL2B Unknown 0.23 0.26 1.16 7.45 × 10−9 Exceed 
6 rs3849942 9 C9orf72 Unknown 0.23 0.26 1.15 1.01 × 10−8 Exceed 
7 Chio and 
others 
(2009) 
rs2708909 7 SUNC1 Encodes a 
40.5-kDa 
nuclear 
envelope 
protein 
Sad1 and 
UNC84 
0.45 0.50 1.17 (1.11–1.23) 6.98 × 10–7 Failed 
8 rs2708851 7 SUNC1 0.45 0.50 1.17 (1.11-1.23) 1.16 × 10–6 Failed 
	  
	  
	  
domain 
containing 1 
9 Iida and 
others 
(2011) 
rs2275294 20 ZNF512B A regulator of 
the TGFβ 
signaling 
pathway 
0.41 0.48 1.32 (1.21-1.44) 6.70 × 10–10 Exceed 
10 Deng and 
others 
(2011) 
rs6703183 1 CAMK1G It encodes 
Ca2+/calmo
dulin-
dependent 
protein 
kinase 
which 
belonging 
to the CaM 
kinase 
family. 
0.34 
(combined) 
0.41 
(combined) 
1.31 (combined) P combined = 
2.92 × 10–8 
Failed 
11 rs8141797 22 SUSD2 SUSD2 is 
mainly 
expressed 
in the brain, 
kidney and 
lung and 
codes for a 
novel 
tumor 
suppressor 
0.10 
(combined) 
0.15 
(combined) 
1.52 (combined) P combined = 
2.35 × 10–9 
Failed 
12 Fogh and 
others 
(2014) 
rs34517613 17 Unknown Unknown 0.13 0.11 0.82, (0.76-0.87) 1.11 × 10–8 Failed 
ALS = amyotrophic lateral sclerosis; Chr = chromosome; CI, confidence interval; MAF: minor allele frequency; OR = odds ratio; Ref. = reference; 
SNP = single nucleotide polymorphisms. 
 
As discussed above there are unique challenges in 
recruiting patients with ALS that make it particularly 
difficult to achieve such large numbers, but given the great 
potential of genetics in this disease, greater emphasis on 
recruitment is required, and further collaborative studies 
encouraged. In addition, large GWAS meta-analytical 
studies including both Caucasian and non-Caucasian 
populations are likely to be informative. 
The Results from GWAS 
In the past 6 years, a conservative estimate of more than 
8000 ALS patients (including patients of white 
European and Asian descent), and many more control 
subjects, have been involved in large scale ALS studies. 
This has resulted in the identification of SNPs that 
appear to be associated with the disorder. The discovery 
of association with the C9orf72 region is the most well 
known of these. In 2010, three ALS-GWASs reported a 
novel susceptibility locus associated with the disease on 
chromosome 9p where C9orf72 is located (van Es and 
others 2009; Laaksovirta and others 2010; Shatunov and 
others 2010). Another independent GWAS of ALS with 
pathologically confirmed FTLD/TDP (frontotemporal 
lobar degeneration/TAR DNA-binding protein) 
(Gijselinck and others 2010) identified the same 
chromosomal region. Linkage of ALS–FTLD to this 
region was first identified in 2006 (Morita and others 
2006; Vance and others 2006), indicating that the 
chromosome 9p gene defect overlaps the candidate 
region for both FTD and ALS. Three genes were found 
in a haplotype block with strong association: 
MOBKL2B, IFNK, and C9orf72. Since this time, the 
hexanucleotide (GGGGCC)n repeat expansion in 
C9orf72 has been identified as the gene defect 
associated with ALS and FTD (DeJesus-Hernandez and 
others 2011; Renton and others 2011). These 
correlations have been reported in many autosomal 
dominantly inherited cases with both FTD and ALS 
(Gijselinck and others 2010; Herdewyn and others 
2012), and recently C9orf72 expansions have also been 
found in cohorts with a variety of neurodegenerative 
diseases including Alzheimer disease, sporadic 
Creutzfeldt-Jakob disease, Huntington disease-like 
syndrome, and other non-specific neurodegenerative 
disease syndromes in addition to FTD and ALS (Beck 
and others 2013). 
The above experimental conclusions become even 
more convincing when the data are subjected to meta-
analysis and pooled analysis. The need for such 
approaches is highlighted by the high rate of non-
replication of findings between ALS GWAS studies  
 
 
 
 
 
 
 
Table 3. Major Replications (Including GWAS) for Variants in ALS Studies. 
Ref. Region of Cohorts Study Method 
Gene Replication 
ITPR2 FGGY DPP6 KIFAP3 
UNC13
A 
Chromosome 9p21 
Locus 
Cronin and others 
(2008) 
Ireland GWAS × × P = 2.53 × 
10–6 
— 
van Es and others 
(2008) 
USA/Dutch Replication — P = 5.04 × 
10–8 
— 
van Es and others 
(2009a) 
North Europe Replication — × — 
Daoud and others 
(2010) 
France and Quebec Replication — × × — 
Landers and others 
(2009) 
Europe/USA GWAS × × × Corrected P = 
.021 
— 
Chio and others 
(2009) 
Italy/Germany/USA GWAS × × × — 
Cronin and others 
(2009) 
Irish/Polish/USA/Dut
ch 
GWAS — × — 
van Es and others 
(2009b) 
Europe/USA GWAS × × × — Table 2 
Shatunov and others 
(2010) 
Europe/USA GWAS × × × — × P = 5·14 × 10–8 
Laaksovirta and 
others (2010) 
Finland GWAS — × 
Fogh and others 
(2011) 
Italy Replication — × — 
Orsetti and others 
(2011) 
Italy Replication — × — 
Iida and others 
(2011b) 
Japan Large-scale 
association 
study 
— 
Iida and others 
(2011a) 
China/Japan Replication — × × 
Kwee and others 
(2012) 
USA High-density 
GWAS 
× × × × × × 
Chen and others 
(2012) 
China Replication × × × × — 
Ratti and others 
(2012) 
Italy Replication — P = 8 × 10–9; OR = 4.0 
Diekstra and others 
(2012) 
Dutch/Belgian/Swedi
sh 
Replication — P < 
.005 
(sic) 
— 
Mok and others 
(2012) 
Europe/USA Meta-analysis — Overall P = .0088 
Deng and others 
(2011) 
China GWAS × × × × × × 
GWAS = genome-wide association studies. Ref. = reference; —, the direct replication for the implicated gene was not included; ×, negative 
results. 
 
(Table 3), which very likely represent type 1 errors due 
to insufficient sample size and statistical power. This is 
a particular problem in genetic studies of ALS, likely 
because the disease is rare and it is hard for individual 
groups to achieve adequate sample sizes. Indeed with 
the exception of the chromosome 9p21 locus, most 
associated SNPs or genes show poor replication in 
different populations. This is also an issue in transethnic 
studies, where for example even the findings for the 
chromosome 9p21.2 locus are inconclusive in Asian 
populations probably because the repeat expansion is 
rare. Robustly proven differences in associations at 
specific loci can be highly informative regarding the 
primary disease-causative variants, which can be hard to 
pinpoint in specific populations, particularly at loci with 
extensive linkage disequilibrium surrounding them. 
Copy Number and Structural 
Variants in Amyotrophic Lateral 
Sclerosis 
Microarray SNPs used in GWAS have modest capability 
to genotype copy number variants (CNVs) and other 
structural variants. When inherited, these are typically in 
linkage disequilibrium with SNPs and at most common 
loci have been detected by GWAS even if the CNV has 
not been typed itself (Wellcome Trust Case Control 
	  
	  
	  
Consortium and others 2010). For ALS only a handful 
of CNV analyses have been reported. The most well 
studied CNV is of the SMN1 gene in which loss of 
function mutations cause autosomal recessive spinal 
muscular atrophy. Several reports suggested that 
duplication of the SMN1 gene is found at a higher 
frequency in ALS patients (Corcia and others 2002; 
Corcia and others 2006; Veldink and others 2005) and 
an association of ALS with SMN1 copy number was 
later confirmed in an analysis of 3500 ALS cases 
(Blauw and others 2012). Aside from the SMN1, other 
CNV analyses in ALS have not had sufficient power to 
confirm correlations of rare events (Cronin and others 
2008). The lack of CNV associations with ALS are 
likely because of limits of current methods for 
genotyping CNVs, or that they are rare rather than that 
they do not occur. Recently, whole genome sequencing 
successfully uncovered de novo CNVs in subjects with 
intellectual disability (Gilissen and others 2014), and a 
similar approach may be required to uncover ALS 
CNVs, if they exist. 
Genome-wide Association Studies 
and Rare or De Novo Variants 
Given the limited sample sizes studied and typically 
weaker linkage disequilibrium around rare and low 
frequency variants, association signals from such 
variants are frequently missed by GWAS. Of particular 
relevance to ALS, GWAS is not capable of detecting de 
novo sporadic mutations that may be responsible for a 
significant fraction of cases, as opposed to variants 
arising in a distant common founder. 
Thus while GWAS is a powerful hypothesis-free 
approach to identifying genetic variants in common 
human diseases, it is not capable of identifying all 
variants, including a range of variants already known to 
be involved in ALS. 
Sequencing for Amyotrophic Lateral 
Sclerosis Gene Mapping 
As GWAS studies are poor at identifying low frequency 
(minor allele frequency [MAF] <5%) and rare (MAF 
<1%) alleles, it has been suggested that large numbers of 
such variants may explain the failure of GWAS to 
identify the variants responsible for a large proportion of 
the heritability of individual diseases (Manolio and 
others 2009). This remains however an unproven 
hypothesis, with little evidence to date to support the 
existence of multiple low frequency or rare variants with 
greater penetrance than common variants. The few 
reported examples of highly penetrant rare alleles have 
generally occurred in genes already known to be 
associated with disease through common variant studies, 
such as IL23R (Momozawa and others 2011), CARD9 
(Rivas and others 2011), and IFIH1 (Nejentsev and 
others 2009). This may represent experimental bias as 
sufficiently large studies to detect rare variants are still 
works in progress. In ALS though, it is clear that rare 
highly and lowly penetrant variants do contribute 
significantly to the disease—these are the variants that 
cause fALS, and are increasingly being identified in 
sALS. 
Next-generation sequencing techniques, including 
whole exome sequencing (WES) and whole genome 
sequencing (WGS) represent a powerful new paradigm 
with regard to addressing monogenic disorders. These 
techniques have enabled gene-mapping studies for rare 
genetic diseases to be performed in the absence of 
multigeneration family material. Instead, either small 
numbers of unrelated affected individuals or small 
families can now be successfully investigated. This has 
proven revolutionary in monogenic disease research, 
stimulating another boom in gene discoveries for 
diseases that had previously not been mappable because 
of insufficient family material. The approach has already 
proven productive in fALS, where it has been used to 
identify disease-causing mutations in VCP and PFN1 
(Johnson and others 2010; Wu and others 2012) that are 
strongly supported as ALS-causing mutations from 
functional studies. Additionally, a WES study using 
samples from 47 sporadic ALS cases and their 
unaffected parents, have identified de novo mutations in 
several candidate genes, including as SS18L1, encoding 
proteins that regulate chromatin (Chesi and others 
2013). 
The same approaches using NGS to map monogenic 
diseases are now being used to map rare high penetrant 
variants in more genetically complex diseases, such as 
sALS. Unlike monogenic diseases, ALS creates a new 
challenge because of the genetic and locus heterogeneity 
and the possibility that ALS is oligo- or polygenic, with 
more than one disease-causing variant operating in 
individuals. This requires much larger sample sizes to be 
studied and more complex analyses to be performed, 
inevitably involving greater cost. However, given that 
ALS may be substantially caused by rare or even de 
novo mutations, these challenges will have to be faced 
to advance our understanding of the genetics of this 
disease. In the past arguments for variants being disease-
causing have been strengthened by evidence of 
segregation with disease in fALS, along with 
identification of mutations in sporadic cases. For PRPH 
and EWSR1, mutations have only been described in 
sALS; however, convincing functional data 
accompanied the variant discovery. Functional methods 
for determining the relevance of rare sequence variants 
identified by NGS to ALS pathogenesis will continue to 
be necessary in the study of genetic causes of sALS. 
The diagnostic benefits that NGS will provide for 
ALS patients and their neurologists are obvious. 
Currently the average time from symptom onset to 
 
 
 
confirmed diagnosis for ALS patients is nearly 1 year, a 
time in which misdiagnosis and sometimes even 
invasive surgery may occur (Paganoni and others 2014). 
Early diagnosis will be vital for clinical trials where 
early treatment before significant damage has occurred 
will be of utmost importance. Early diagnosis may be 
facilitated by sequencing early symptomatic cases, or by 
screening in families known to carry high penetrant 
variants. Furthermore, knowledge of the genetic cause 
of ALS in patients participating in clinical trial will 
informative, where in the context of a genetically 
heterogeneous disease success or failure of treatments 
may depend on the original genetic cause. Until 
treatments reach the clinic, the multitude of researchers 
using donated material from ALS patients to try to 
understand why motor neurons degenerate, will benefit 
by being able to group samples based on genetics to 
more meaningfully interpret data generated. 
Limitations of Next-Generation 
Sequencing in Amyotrophic Lateral 
Sclerosis 
Although there are clear advantages to NGS, it is not 
without drawbacks. As the name implies, WES is 
designed to capture the whole exome. In reality it does 
not, and about 5% of the exome is not captured in 
typical exome sequencing experiments. Furthermore, 
not all monogenic diseases are caused by mutations in 
coding regions, and therefore may not be detected using 
exome sequencing. An additional technical challenge is 
that WES using short-read sequencing technologies such 
as Illumina sequencing chemistry has difficulties in 
sequencing repeats and insertion/deletions, as the short 
reads cannot be unambiguously aligned against 
reference genomes. Some relevant examples of the 
limitations of WES exist in ALS gene-mapping include 
the following: 
• TDP-43 and FUS are known to regulate splicing 
of pre-mRNA by binding to sites within introns 
(Arnold and others 2013; Lagier-Tourenne and 
others 2012; Polymenidou and others 2011); WES 
may not identify mutations at these binding sites 
and thus if mutations at sites in genes targeted by 
TDP-43 or FUS were involved in ALS, they 
would not be detected by WES. 
• An intronic hexanucleotide repeat in C9orf72 gene 
has been identified though linkage mapping and 
several GWASs and the finding has been 
replicated independently. This locus is difficult to 
detect by WES as it is intronic, and also by WGS, 
because of the difficulty aligning short-read data 
of stretches of microsatellite and minisatellite 
DNA sequences. This weakness may be overcome 
using longer read technologies such as single 
molecule real-time sequencing (Pacific Bioscience 
sequencing), which has a read length of up to 10 
kb, compared with short 2 × 100- or 2 × 150-bp 
paired-end reads typically produced by, for 
example, Illumina sequencing. 
Thus, sequencing is not at this point a technology 
capable of identifying all potential ALS-causative 
variants, and it should be noted still requires the large 
sample sizes discussed above to achieve adequate 
power. NGS approaches have great potential and are 
capable of identifying a substantial fraction of variants 
that are not within the scope of GWAS. Advances in 
sequencing technologies, decreasing cost of sequencing 
and initiatives such as Project MinE 
(www.projectmine.com) aiming to raise funds and 
generate whole genome sequence from 15,000 ALS 
subjects, will lead to data being rapidly produced over 
the coming years, allowing in-depth genetic analysis. 
Genome-wide Methylation Analysis 
Several different methods involving either microarrays 
or DNA sequencing now enable genome-wide 
characterization of DNA methylation. 
Epigenetic variation including DNA methylation is a 
major determinant of gene transcription. Improved 
methods to assess DNA methylation in particular has led 
to increasing interest in the role of epigenetic variation 
in human disease, including ALS (Figueroa-Romero and 
others 2012). An early microarray based analysis of 
methylated DNA immunoprecipitated from post-mortem 
brain found differential gene methylation in ALS cases 
(Morahan and others 2009) and a second using ALS 
spinal cord reported changes in global methylation and 
hydroxymethylation (Figueroa-Romero and others 
2012). These studies represent an initial identification of 
epigenetic regulatory changes in ALS, however, were 
only performed on 10 and 12 ALS samples, 
respectively. Larger studies with more sensitive and 
robust methods are clearly required to uncover the 
contribution of epigenetics to ALS. 
Aside from genome-wide methylation analyses, 
several gene specific analyses of CpG methylation 
within promoters of ALS genes and candidate genes 
have been performed. No difference in DNA 
methylation was observed in ALS cases in the promoter 
regions of SOD1, VEGF (Oates and Pamphlett 2007) 
and EAAT2 (Yang and others 2010). However, CpGs 
upstream of the C9orf72 repeat expansion in some 
expansion carriers were hypermethylated and the 
corresponding mRNA was down-regulated in a limited 
number of samples tested(Xi and others 2013). 
Methylation of upstream CpG islands is not novel in 
terms of repeat expansion mutations and the role that 
methylation at the C9orf72 locus plays in ALS 
	  
	  
	  
pathogenesis is yet to be determined and requires further 
analysis in larger cohorts of carriers. 
Other Methods Combined with 
Whole Genome Strategies 
Commonly, alleles showing a correlation between allele 
load and expression levels are defined as expression 
quantitative trait loci (eQTL). Diekstra and others 
(2012) conducted a two-stage genome-wide screen for 
eQTLs associated with ALS. Data from a two-stage 
GWAS were combined to prioritize eQTLs identified in 
the first stage. While identifying candidate genes for 
sporadic ALS, most notably CYP27A1, the study 
demonstrated the potential of an integrated approach in 
identifying causative genetic variants in ALS. 
Both methylation and expression analyses in ALS 
suffer from issues related to tissue sampling because the 
site of disease pathology is not amenable during the life 
of the patients. Postmortem material, although valuable, 
represents end-stage of disease when significant damage 
and neuron loss has already occurred. It is also difficult 
to obtain the large numbers of post-mortem samples 
required for genome-wide analyses. Other sources of 
RNA and DNA that are more suitable for the large 
studies required for such a genetically and clinically 
heterogenous disorder as ALS will need to be 
considered. 
Expectation for Future Amyotrophic 
Lateral Sclerosis Genetic Studies 
Genetic discoveries in ALS have provided major 
advances in our understanding of the diseases causation, 
and the development of new methods for gene mapping 
particularly using high-throughput sequencing promises 
much. There is also a clear need to perform further 
studies in populations of different ethnicity. Systems 
biology approaches including multiple modalities such 
as DNA sequencing, transcriptomics, proteomics and 
epigenomics are likely to be useful, particularly with 
functional analysis of the mechanisms by which genetic 
mutations cause ALS. As ever there is no “one-size-fits-
all” solution to ALS research, but the increasing 
capability of our research tools is bringing major 
advances to studies of this disease. In other disease areas 
such as immune-mediated diseases, success in gene-
mapping has been so great in the past 5 years of the 
GWAS era that the bottleneck has clearly moved on to 
determining how disease-associated variants lead to 
disease. The authors expect that this will similarly be the 
problem facing ALS research in the near future. 
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